| abstract |
Disclosed herein are IL-4 cytokine compositions with enhanced biological activity that have increased selectivity for IL-4 cytokine receptors, and methods of their use. These compositions include interleukin-4 (IL-4) muteins. The disclosed methods include administering IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases, or to increase hematopoietic cell populations. [Selection] Figure 1 |